New York City, USA, and Zurich, Switzerland, July 29, 2021 - We are excited to announce that Immunai, a global AI company leading in single-cell multi-omics technologies, is completing the acquisition of Nebion.
Nebion, which will continue to operate under that name, will become a wholly owned subsidiary of Immunai. Nebion’s high-quality curated data together with Immunai’s expertise in AI-powered immune profiling will extend Immunai’s target discovery and drug development capabilities.
The integration of both companies will take place over the next months. As with all important business decisions, Nebion will work closely with its clients, partners, and employees to make the integration process as smooth as possible. Of course, in the meantime all customers will continue to receive the same high-quality service and commitment, which they have come to expect.